Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.13
-0.0400-3.42%
Post-market: 1.11-0.0200-1.77%19:53 EDT
Volume:432.11K
Turnover:490.39K
Market Cap:14.93M
PE:-1.00
High:1.17
Open:1.17
Low:1.11
Close:1.17
Loading ...

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
26 Jun

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

MT Newswires Live
·
25 Jun

Silo Pharma Enters Into Letter of Intent to Form Joint Venture With Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

THOMSON REUTERS
·
25 Jun

BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics

Reuters
·
25 Jun

Silo Pharma: Formation of Strategic Joint Venture With Hoth Therapeutics

THOMSON REUTERS
·
25 Jun

Silo Pharma: Joint Venture to Develop First-in-Class Gdnf-Based Therapy Licensed From U.S. Dept of Veterans Affairs

THOMSON REUTERS
·
25 Jun

Hoth Therapeutics Advances HT-001 for Cancer Treatment

TIPRANKS
·
25 Jun

BRIEF-Hoth Therapeutics Says 100% Of Patients Achieved Primary Endpoint In HT-001 Phase 2A Trial

Reuters
·
24 Jun

Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study

TIPRANKS
·
24 Jun

Hoth Therapeutics Announces 100% Response Rate in Phase 2a Trial for HT-001, Targeting EGFR Inhibitor-Induced Skin Toxicities

Reuters
·
24 Jun

Hoth Therapeutics Inc - Topical Therapy Well Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
24 Jun

Hoth Therapeutics Ht-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects

THOMSON REUTERS
·
24 Jun

Hoth Therapeutics Inc - 100% of Patients Achieved Primary Endpoint in Phase 2a Trial

THOMSON REUTERS
·
24 Jun

Hoth Therapeutics Announces Key Opinion Leader Event to Present Interim Phase 2 Trial Results for HT-001, a Novel Therapy for Cancer-Related Skin Toxicities

Reuters
·
23 Jun

Hoth Therapeutics Regains Nasdaq Compliance on June 18

TIPRANKS
·
20 Jun

Hoth Therapeutics Regains Nasdaq Compliance, Clears Key Listing Hurdle

Reuters
·
19 Jun

Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth

THOMSON REUTERS
·
19 Jun

Hoth Therapeutics Announces Positive Preclinical Safety Data for Cancer-Fighting HT-KIT, Paving Way for IND Filing

Reuters
·
18 Jun

Hoth Therapeutics Inc - Ht-Kit Shows Dose-Dependent Liver Activity With Zero Toxicity

THOMSON REUTERS
·
18 Jun

Hoth Therapeutics Inc - No Adverse Effects on Kidney, Spleen, or Thymus

THOMSON REUTERS
·
18 Jun